GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Holdings Corp. (Nasdaq: WGS) has announced the granting of 69,089 restricted stock units (RSUs) to three newly-hired employees, effective January 14, 2025.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/17/2025 - 04:30 PM EST

STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of January 14, 2025, the compensation committee of GeneDx’s board of directors granted a total of 69,089 restricted stock units (“RSUs”) to three newly-hired employees as inducements material to each employee entering into employment with GeneDx. The foregoing includes 37,497 RSUs granted to Bryan Dechairo, as an inducement material to the employment of Mr. Dechairo as Chief Operating Officer. The RSUs were granted under GeneDx’s 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs granted to Mr. Dechairo and the two other newly-hired employees will vest in equal annual installments over a four-year period, subject to the employee’s continued service with GeneDx on each applicable vesting date. Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement.

About GeneDx

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.